Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of High-dose CKD-385 in Healthy Volunteers
NCT04906798Phase 1Unknown
- Sponsor
- Chong Kun Dang Holdings
- Start
- Jun 2021
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of carvedilol in hypertension (HTN), heart failure (HF) and angina pectoris (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoint: Area Under the Curve to the last measurable concentration. Status: unknown.
02
Drugs
carvedilol
03
Conditions
hypertension (HTN)heart failure (HF)angina pectoris
Beyond the preview
Go deeper on NCT04906798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04906798.